| 131I-zaptuzumab对体外培养肿瘤细胞存活的影响 |
| 投稿时间：2015-02-02 修订日期：2015-02-27 点此下载全文 |
| 引用本文：郝振亮,蔡炯,郑德先.131I-zaptuzumab对体外培养肿瘤细胞存活的影响[J].医学研究杂志,2015,44(9):35-39 |
| DOI：
10.11969/j.issn.1673-548X.2015.09.010 |
| 摘要点击次数: 1039 |
| 全文下载次数: 902 |
|
| 基金项目:国家自然科学基金资助项目(30500573,30670741) |
|
| 中文摘要:目的 为提高单克隆抗体治疗肿瘤效果,研究测试放射性核素131I标记的单克隆抗体zaptuzumab 对体外培养肿瘤细胞的杀伤作用。 方法 实验采用3种肿瘤细胞,分别是人A549肺腺癌、人H460大细胞肺癌和人MGC-803胃腺癌细胞。每组细胞采用4种不同的处理:分别是生理盐水、zaptuzumab、131I-zaptuzumab和131I。处理12h后用MTS法测定细胞活性,用ANOVA分析各组之间的统计学差异,了解131I-zaptuzumab对肿瘤细胞存活的影响。 结果 131I-zaptuzumab的处理使人A549肺腺癌细胞的存活率降低37.9%,而zaptuzumab和131I处理分别使人A549肺腺癌细胞的存活率降低8.7%和1.9%;131I-zaptuzumab的处理使人H460大细胞肺癌的存活率降低53.4%,而zaptuzumab和131I处理使人H460大细胞肺癌细胞的存活率降低15.1%和18.1%;131I-zaptuzumab使人MGC-803胃腺癌存活率降低13.4%,而zaptuzumab和131I处理使存活率降低10.2%和8.4%。 结论 131I-zaptuzumab与zaptuzumab相比,能够更有效地杀伤人A549肺腺癌和H460大细胞肺癌细胞,提示靶向死亡受体5的放射免疫治疗的可行性。 |
| 中文关键词:放射性同位素碘 zaptuzumab A549 H460 MTS |
| |
| Effect of 131I-zaptuzumab on the Survival of Tumor Cells in vitro |
|
|
| Abstract:Objective To improve the therapy effect of monoclonal antibody on tumor, we tested the killing effect of monoclonal antibody zaptuzumab carrying therapeutic nuclide 131I on tumor cells in vitro. Methods Three different tumor cell lines including human lung adenocarcinoma A549 cells, human large cell lung cancer H460 cells and human gastric adenocarcinoma MGC-803 cells were used in this experiment. The cells were treated with saline, zaptuzumab, 131I-zaptuzumab and 131I respectively for 12h at 37℃ in the cell incubator. The cell viability was determined by MTS method. ANOVA t-test was used to analyze the difference between different groups for valuating the effect of 131I-zaptuzumab on the survival of tumor cells. Results The survival ratio of human lung adenocarcinoma A549 cells after 131I-zaptuzumab treatment reduced 37.9%, while those treated with zaptuzumab reduced 8.7% and those treated with 131I reduced 1.9%. The survival ratio of human large cell lung cancer H460 cells after 131I-zaptuzumab treatment reduced 53.4%, while those treated with zaptuzumab reduced 15.1% and those treated with 131I reduced 18.1%.The survival ratio of human gastric adenocarcinoma MGC-803 cells after 131I-zaptuzumab treatment reduced 13.4%, while those treated with zaptuzumab reduced 10.2% and those treated with 131I reduced 8.4%. Conclusion Compared with zaptuzumab, 131I-zaptuzumab has stronger anti-tumor activity to human lung adenocarcinoma A549 cells and large cell lung cancer H460 cells. These data indicate that the feasibility of radioimmunotherapy targeting death receptor 5. |
| keywords:Radioiodine isotope Zaptuzumab A549 H460 MTS |
| 查看全文 查看/发表评论 下载PDF阅读器 |
